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We describe an X-linked genetic syndrome associated with mutations in TAF1 and manifesting with global developmental delay, intel-
lectual disability (ID), characteristic facial dysmorphology, generalized hypotonia, and variable neurologic features, all in male individ-
uals. Simultaneous studies using diverse strategies led to the identification of nine families with overlapping clinical presentations and
affected by de novo or maternally inherited single-nucleotide changes. Two additional families harboring large duplications involving
TAF1were also found to share phenotypic overlap with the probands harboring single-nucleotide changes, but they also demonstrated a
severe neurodegeneration phenotype. Functional analysis with RNA-seq for one of the families suggested that the phenotype is associ-
ated with downregulation of a set of genes notably enriched with genes regulated by E-box proteins. In addition, knockdown and
mutant studies of this gene in zebrafish have shown a quantifiable, albeit small, effect on a neuronal phenotype. Our results suggest
that mutations in TAF1 play a critical role in the development of this X-linked ID syndrome.Transcription factor II D (TFIID) consists of TATA binding
protein (TBP) and 12–14 TBP-associated factors (TAFs).
TFIID promotes transcriptional initiation by recognizing
promoter DNA and facilitating the nucleation of other
general transcription factors for assembly into a functional
pre-initiation complex,1–5 and it also functions as a co-acti-
vator by interacting with transcriptional activators.1 Sub-
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when they are disrupted.6–12 Indeed, variants in TAF2
(MIM: 604912) and TBP (MIM: 600075) have been impli-
cated in intellectual disability (ID) and developmental
delay with or without corpus callosum hypoplasia.10,11,13
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that mutations in TAF6 (MIM: 602955), encoding a
component of TFIID, play an important role in the patho-
genesis of this syndrome.14 CdLS is a phenotypically and
genetically heterogeneous syndrome characterized by
distinct facial features, hirsutism, developmental delay,
ID, and limb abnormalities,15 and mutations in several
different genes have been implicated in contributing to
this heterogeneous clinical presentation.16–19 Two muta-
tions in TAF6 were implicated in disease pathogenesis in
some individuals with phenotypic features of CdLS and
were shown, through biochemical investigations, to
reduce binding of TAF6 to other core components of
TFIID.14
A recent paper nominated TAF1 (MIM: 313650) as a
candidate gene for ID on the basis of segregation of
missense variants in two different pedigrees; however, no
clinical information other than ID was provided.20 TAF1
encodes the largest subunit of the TFIID complex and
has been ranked 53rd among the top 1,003 constrained hu-
man genes in a recent population-scale study,21 suggesting
that TAF1 plays a critical role in normal cellular function.
Previous work in Drosophila cells has shown that TAF1
depletion increases the magnitude of the initial transcrip-
tion burst and causes delay in the shutoff of transcription
upon removal of the stimulus.22 The authors showed that
the magnitude of the transcriptional response to the same
signaling event, even at the same promoter, can vary
greatly depending on the composition of the TFIID com-
plex in the cell. In addition, and consistent with the
notion that TAF1 is important in controlling the binding
patterns of TFIID to specific promoter regions, this study
showed that the set of genes conferring increased expres-
sion were enriched with TATA-containing promoters, sug-
gesting an association between the depletion of TAF1 and
increased expression of genes with the TATA motif. The
genomic region containing TAF1 has also been suggested
to play an important role in X-linked dystonia-parkin-
sonism (XDP [MIM: 314250]), although the exact me-
chanism remains undetermined6,8,23 (Dy et al., 2015,
Movement Disorders, abstract). XDP is an X-linked reces-
sive movement disorder characterized by adult-onset dys-
tonia and parkinsonism, which lead to eventual death as
a result of oropharyngeal dystonia or secondary infec-
tions.24 Studies investigating the molecular basis of XDP
have demonstrated aberrant neuron-specific expression
levels of TAF1 isoforms in neuronal tissue containing
TAF1 variants. Herzfeld et al. corroborated previous reports
suggesting that a reduction in TAF1 expression is associ-
ated with large-scale expression differences across hun-
dreds of genes,6 and studies in rat and mouse brain have
also corroborated the importance and relevance of TAF1
expression patterns specific to neuronal tissues.7,9
In this study, we describe a recognizable syndrome attrib-
uted to mutations in TAF1. This work represents a collabo-
rative research effort between independent groups engaged
in studying themolecular basis of human disease. A ‘‘geno-
type-first’’ approach25 was used for finding families withThe Americanvariants in TAF1. This approach included phenotypic eval-
uations and screening of families with individuals
harboring mutations in TAF1. This process was facilitated
by the use of databases such as DECIPHER and reporting
initial findings on the BioRxiv preprint server.26 These ef-
forts culminated in a study cohort of 14 affected individuals
from 11 unrelated families. Twelve of these individuals
(from nine unrelated families) contain single-nucleotide
changes in TAF1, and two (from two unrelated families)
have large duplications involving TAF1. Written informed
consentwasobtained fromall studyparticipants for all fam-
ilies, except in those instances when exomes were ordered
throughGeneDx on clinical grounds, and researchwas car-
ried out in compliance with the Declaration of Helsinki.
Shared phenotypic features representing the cardinal
characteristcs of this syndrome (see Figures 1 and 2, Tables
1, 2, and S5, and Movies S1, S2, S3, S4, S5, S6, and S7)
include global developmental delay, ID, characteristic
facial dysmorphologies, and generalized hypotonia.
Shared facial dysmorphologies include prominent supraor-
bital ridges, down-slanted palpebral fissures, sagging
cheeks, a long philtrum, low-set and protruding ears, a
long face, a high palate, a pointed chin, and anteverted
nares. The probands also share a characteristic gluteal
crease with a sacral caudal remnant (Figure S13), although
spineMRI on two probands did not show anymajor under-
lying defect (Figure S8). The affected individuals have
generalized hypotonia, as well as joint hypermobility.
Other widely shared features include hearing impairment,
microcephaly, and hypoplasia of the corpus callosum
(Figure S7 and Table S5). Interestingly, probands 8A (II-1
in family 8; Figure 2) and 11A (II-1 in family 11; Figure 3)
are also affected by abnormal development of the thoracic
cage. Some additional neurological features include spastic
diplegia, dystonic movements, and tremors. Individuals
8A, 10A (IV-3 in family 10; Figure 3), and 11A have progres-
sive symptoms, and one individual (11A) died of severe
cardiopulmonary insufficiency attributed to an infection.
Importantly, probands bearing duplications of TAF1 (10A
and 11A) not only demonstrate severe and progressive
neurodegeneration but also do not share some of the
more common features of the rest of the probands (see
Table 1 and Figures 1 and 3 for comparison). Detailed clin-
ical information is included in the Supplemental Note.
Several strategies were used for identifying candidate
disease-related sequence variation. These included whole-
genome sequencing, exome sequencing, targeted gene-
panel sequencing, and microarray-based strategies (Figures
S1–S5 and Tables S1–S4). Sanger sequencing was used for
validating sequence variations. Many of the families stud-
ied here underwent genotyping via clinical microarrays or
gene-specific sequencing for a small number of genomic
regions. See the Supplemental Data for more-detailed de-
scriptions of the sequencing and analysis methods used
for each family. All 14 affected individuals were found to
contain TAF1 sequence variants, the majority of which
(11 out of 14) are missense variants. One proband (II-1 inJournal of Human Genetics 97, 922–932, December 3, 2015 923
Figure 1. Images of the Facial Phenotype from Families 1, 2, and 4–9
Cardinal facial dysmorphologies include prominent supraorbital ridges (seen in 1A, 1B, 2A, 6A, 8A–8C, and 9A), down-slanted palpe-
bral fissures (1A, 1B, 2A, 4A, 5A, 6A, 8A–8C, and 9A), sagging cheeks (1A, 1B, 5A, 8A–8C, and 9A), a long philtrum (1A, 1B, 2A, 4A, 5A,
8A–8C, and 9A), low-set and protruding ears (1A, 1B, 2A, 4A, 5A, 6A, 8A–8C, and 9A), a long face (1A, 1B, 2A, 5A, 6A, 8A–8C, and 9A),
a high palate (5A, 6A, 8A–8C, and 9A), a pointed chin (1A, 1B, 2A, 4A, 5A, 6A, and 8A–8C), and anteverted nares (2A, 4A, 5A, 7A,
8A–8C, and 9A).family 5; 5A in Figure 2) was found to have a variant that
influences TAF1 splicing, and two probands (10A and
11A) were found to have a duplication that involves
TAF1. As stated above, the two probands with duplications
exhibit less overlap with those who harbor single-nucleo-
tide changes (see Table 1) and exhibit severe progressive
neurologic impairment. All of the mutations reported
here, including the duplications, are de novo or co-segre-
gate with the phenotype in other affected male individuals
(see Figures 2 and 3).
Families 1 and 10 were tested for X chromosome in-
activation, which showed that female carriers of TAF1
mutations and duplications demonstrate highly skewed
inactivation (99:1). The female carriers in families 5 and
11 were not informative for the polymorphic CAG repeat
in the human androgen-receptor gene.
All missense variants were found to affect evolutionarily
conserved residues (Figure 2B) and were not present at any
frequency in public databases such as dbSNP137, 1000
Genomes phase 1, the NHLBI Exome Sequencing Project
Exome Variant Server (ESP6500), or ExAC Browser version
0.2, which contains allelic information derived from
~60,000 exome sequences. The TAF1 missense variants
were also predicted to be deleterious by a range of pre-
diction software (CADD, SIFT, GERPþþ, and phyloP)924 The American Journal of Human Genetics 97, 922–932, Decemb(Figure 2B). The splice-site variant discovered in family 5
was not predicted to be deleterious by the prediction
software listed. However, this variant does not change
the amino acid content of the predicted protein; instead,
it affects TAF1 splicing in both the mother and the pro-
band (Figure S11). In addition, the single-nucleotide vari-
ants (SNVs) described here fall within TAF1 regions that are
relatively sparsely covered by non-synonymous sequence
variations reported in the ExACBrowser (Figure 2C). Indeed,
four of these missense variants (c.2419T>C [p.Cys807Arg],
c.2926G>C [p.Asp976His], c.3736C>T [p.Arg1246Trp],
and c.3708A>G [p.Arg1228Ilefs*16]) were found to be
within the two TAF1 regions that are significantly un-
derrepresented by non-synonymous sequence variation
reported in the ExAC Browser when restricted to European
and Latin populations (Figure 2C). Additional variants
found in families 6 and 7 (c.4549A>C [p.Asn1517His] and
c.4355G>A [p.Arg1431His]) also fall within a region
that is underrepresented by non-synonymous sequence
variation, although this last cluster is not statistically
significant (p value ¼ 0.29) (see Supplemental Data for
further details).
Recent structural work in yeast points to an epigenetic
role of the TAF1-TAF7 complex in general TFIID function
and/or assembly of the pre-initiation complex (PIC).4,5er 3, 2015
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Figure 2. TAF1 Domains, Variant Scores, and ExAC Sequence Variation Plot
(A) Pedigree drawings of the nine families who were found to harbor TAF1 SNVs (NCBI Gene ID: 6872 according to the GRCh37.p13
assembly). Black dots indicate maternal carriers.
(B) All nine SNVs are listed and annotated with CADD, SIFT, GERPþþ, and phyloP scores (which indicate conservation across 99 verte-
brate genomes and humans). All of the SNVs are considered to be potentially deleterious by all of the listed annotations, except for
c.3708A>G, which is a splice-site variant and as a consequence is not necessarily expected to be categorized as deleterious by any of
the listed scores, because it does not affect amino acid composition of the predicted protein.
(C) Known TAF1 domains are shown with respect to their corresponding genic positions. All but non-synonymous variants reported in
the ExAC Browser for TAF1 are plotted below as lines; white and gray indicate exon boundaries. Red lines indicate the relative positions
of the eight missense variants described in this paper (see Table 2). Numerals link the sequence variants shown on the ExAC plot to their
familial origin, and those noted with a star fall within TAF1 regions that are significantly underrepresented by non-synonymous
sequence variation in the ExAC Browser in European and Latin populations (p values of 0.032 and 0.037 for the first [c.2419T>C,
c.2926G>C, and c.3736C>T] and second [c.3708A>G ] clusters, according to Cucala’s hypothesis-free multiple scan statistic with a var-
iable window27).Human TAF1 is a 1,893 amino acid multifunctional pro-
tein that has been reported to possess activities related to
DNA promoter binding, histone acetylation, and protein
phosphorylation.28–31 The histone acetyltransferase
(HAT) activity of TAF1 can be blocked by TAF7 bind-
ing.32,33 Studies suggest that phosphorylation of TAF7 at
Ser264 causes release from TFIID and thus alleviates its in-
hibitor effect on TAF1.34 Therefore, mutations that disrupt
this inhibitory protein-protein interaction could have
devastating effects on gene-expression profiles during hu-
man development. Intriguingly, four of the eight missense
variants in TAF1 change residues that are conserved in
higher eukaryotes and map to domains important for
TAF7 binding. Substitutions p.Cys807Arg, p.Pro596Ser,
and p.Asp976His from families 2, 8, and 9, respectively,
fall within an evolutionarily conserved central domain
(DUF3591) that spans residues 586–1,049. DUF3591 en-
compasses the TAF1 HAT domain and numerous points
of contact with TAF7.35 The recently reported human
TAF1-TAF7 crystal structure reveals that Cys807 is buried
in the center of a heterodimeric triple barrel formed by seg-
ments of TAF1 and TAF7.35 Replacement of the cysteine, a
polar amino acid capable of disulfide-bond formation,
with the large basic amino acid arginine (p.Cys807Arg) is
predicted to destabilize the triple-barrel fold and poten-
tially interfere with the interaction between TAF1 and
TAF7. The p.Asp976His substitution also has the potentialThe Americanto disrupt TAF1-TAF7 binding. The acidic Asp976maps to a
separate TAF1-TAF7 protein interface within DUF3591
and undergoes intermolecular hydrogen binding in the
highly conserved glycine-rich loop of TAF1. This loop
interacts extensively with a highly conserved Arg-rich
motif in TAF7. The acidic-to-basic amino acid change
(p.Asp976His) has the potential to disrupt the architecture
of the glycine-rich motif and its ability to effectively bind
to TAF7. The p.Arg1246Trp substitution described in this
work and the published p.Arg1190Cys TAF1 variant20
reside in the RAP74-interacting domain (RAPiD) of TAF1
(residues 1,120–1,279), which also has been shown to be
important for TAF7 binding.35,36 The number of TAF1 de
novo missense mutations co-segregating with ID syn-
dromes and predicted to affect TAF7 binding is quite strik-
ing, further strengthening the importance of TAF7 in the
regulation of TAF1 function. TAF1 is a difficult protein to
work with in isolation, and it is likely to be unstable in
the absence of a binding partner, such as TAF7.4,32,35
Thus, we speculate that variants that are not within any
known protein domain (i.e., p.Ile1337Thr) might affect
domain packing of TAF1, and this might interfere with
the TAF1-TAF7 interacting surface4,35 or mark the protein
for proteolytic degradation.
Bromodomains are a common feature of transcription
factors that possess HATactivity. TAF1 contains two bromo-
domains (Bromo1: 1,397–1,467; Bromo2: 1,520–1,590),Journal of Human Genetics 97, 922–932, December 3, 2015 925
Table 1. Summary of the Clinical Features of TAF1 ID Syndrome
Features (Human Phenotype Ontology Nos.)
Proband
1A 1B 2A 3A 4A 5A 6A 7A 8A 8B 8C 9A 10Aa 11Aa
Sex M M M M M M M M M M M M M M
Age (years) 15 13 5 6 9 3 22 11 9 4 1 3 16 8
Postnatal growth retardation
(HP: 0008897)
þ þ þ þ þ þ   þ þ þ þ UK þ
Delayed gross motor development
(HP: 0002194)
þ þ þ þ þ þ þ þ þ þ þ þ þ þ
Delayed speech and language development
(HP: 0000750)
þ þ þ þ þ þ þ þ þ þ þ UK þ þ
Oral-pharyngeal dysphagia (HP: 0200136) þ þ þ þ UK þ UK  þ þ þ UK þ UK
Prominent supraorbital ridges (HP: 0000336) þ þ  þ UK  þ  þ þ þ þ þ þ
Downslanted palpebral fissures (HP: 0000494) þ þ þ  þ þ þ  þ þ þ  þ UK
Sagging cheeks þ þ    þ   þ þ þ þ þ þ
Long philtrum (HP: 0000343) þ þ þ þ þ þ  þ þ þ þ þ  
Low-set ears (HP: 0000369) þ þ þ þ þ þ þ  þ þ þ þ  þ
Protruding ears (HP: 0000411) þ þ þ þ þ þ þ  þ þ þ   þ
Long face (HP: 0000276) þ þ   UK þ þ  þ þ þ þ þ þ
High palate (HP: 0000218) UK UK þ þ  þ þ  þ þ þ þ þ þ
Pointed chin (HP: 0000307) þ þ   þ þ þ  þ þ þ  þ þ
Anteverted nares (HP: 0000463)   þ þ þ þ  þ þ þ þ þ  þ
Hearing impairment (HP: 0000365) þ þ þ þ UK þ   þ þ þ  UK 
Chromic otitis media (HP: 0000389) þ þ þ  þ þ  þ þ þ þ  UK 
Strabismus (HP: 0000486) þ þ þ þ UK þ þ  þ   þ þ 
Microcephaly (HP: 0000252) þ þ þ þ þ   þ þ þ þ þ  
Hypoplasia of the corpus callosum (HP: 0002079) þ þ þ UK þ þ þ UK þ þ þ þ UK 
Generalized hypotonia (HP: 0001290) þ þ þ þ þ þ þ  þ þ þ þ  þ
Unusual gluteal crease with sacral caudal
remnant and sacral dimple (abnormal sacral
segmentation [HP: 0008468] and prominent
protruding coccyx [HP: 0008472])
þ þ þ þ þ þ þ þ þ þ þ þ UK 
Joint hypermobility (HP: 0001382) þ þ  þ UK þ   þ þ þ þ  UK
Autistic behaviors (HP: 0000729) þ þ þ  UK UK þ þ þ þ þ  þ þ
Intellectual disability (HP: 0001249) þ þ þ þ þ UK þ þ þ þ þ þ þ þ
This table demonstrates clinical features shared by eight or more probands across all affected individuals in the families. See Table S5 for a more comprehensive
phenotypic table that includes phenotypic and clinical idiosyncrasies. Abbreviations are as follows: M, male; and UK, unknown.
aProbands containing duplications; they are generally less similar to the probands containing SNVs and share fewer common clinical features.each ofwhich consists of a bundle of four alpha helices that
form a hydrophobic pocket that can recognize acetylated
lysines found on the N-terminal tails of histones.37,38 A
close examination of the published TAF1 bromodomain
structure revealed that the p.Arg1431His substitution in
family 7 is a surface residue on one face of the alpha helix.
It forms hydrogen bonds with two residues on a nearby
helix, most likely playing a supporting role in maintaining
the bromodomain fold. Substitution p.Arg1431His could
affect the stability of the acetyl-lysine ligand binding site
in TAF1 and alter promoter recognition.926 The American Journal of Human Genetics 97, 922–932, DecembAs an initial attempt to explore whether a biological
signature could be seen on the level of the transcriptome
for at least one of the mutations in the above families,
we conducted RNA sequencing (RNA-seq) with RNA iso-
lated from the blood of family 1. Blood was collected
from the two probands, their parents, and the maternal
grandparents. Except for the single blood draws for the
grandparents, two blood draws were taken on separate
days for each subject. RNA libraries were generated, and
the final pooled library was sequenced on a HiSeq 2000
across three lanes (paired-end 100 bp). A mean ofer 3, 2015
Table 2. Summary of TAF1 Variants across All Affected Individuals in This Study
Proband Inheritance Genetic Background TAF1 Mutation (hg19)
1A maternal European decent chrX: g.70621541T>C (c.4010T>C; p.Ile1337Thr)
1B maternal European decent chrX: g.70621541T>C (c.4010T>C; p.Ile1337Thr)
2A de novo European decent chrX: g.70607243T>C (c.2419T>C; p.Cys807Arg)
3A de novo European decent chrX: g.70618477C>T (c.3736C>T; p.Arg1246Trp)
4A de novo European decent chrX: g.70601686T>A (c.1514T>A; p.Ile505Asn)
5A maternal Ecuadorian chrX: g.70618449A>G (c.3708A>G; r.[3708a>g;
3681_3708del28]; p.Arg1228Ilefs*16)
6A de novo European decent chrX: g.70643003A>C (c.4549A>C; p.Asn1517His)
7A de novo British chrX: g.70627912G>A (c.4355G>A; p.Arg1431His)
8A maternal Colombian chrX: g.70602671C>T (c.1786C>T; p.Pro596Ser)
8B maternal Colombian chrX: g.70602671C>T (c.1786C>T; p.Pro596Ser)
8C maternal Colombian chrX: g.70602671C>T (c.1786C>T; p.Pro596Ser)
9A de novo Spanish chrX: g.70612503G>C (c.2926G>C; p.Asp976His)
10A maternal Albanian 0.423 Mb duplication including TAF1 and other genes at
Xq13.1(70,370,794–70,794,385); deletion containing KANSL1
and other genes at 17q21.31 (0.63 Mb)
11A de novo Greek 0.42 Mb duplication including TAF1 and other genes:
arr Xq13.1(70,287,519–70,711,110)3249,792,652 (SD ¼ 11,666,119) properly paired reads were
generated, and a mean spliced mapping percentage of
85.41% (SD ¼ 7.1%) per sample was observed (Table S6).
HISAT39 was used for spliced alignment to UCSC Human
Genome Browser hg19, and Stringtie40 was used for quan-
tifying known transcripts. Cuffdiff41 was used for perform-
ing differential expression analysis, and CummeRbund42
was used for analyzing, filtering, and visualizing the results
from the Cuffdiff differential-expression analysis. Gene-set
enrichment analyses were performed with WebGestalt,43
which uses Molecular Signatures Database (MSigDB) for
transcription-factor targets,44 Kyoto Encyclopedia of
Genes and Genomes (KEGG),45 Gene Ontology (GO),46
and Human Phenotype Ontology (HPO)47 to obtain gene
annotations and set-inclusion information. We used
various analysis tools in the CummeRbund package42 to
evaluate the quality of our RNA-seq data and analysis for
family 1 (Figure S10).
We found 213 genes (Table S7) to be differentially ex-
pressed between the two affectedmale probands from fam-
ily 1 and their unaffected parents and grandparents. Of
these 213 genes, 179 were expressed less (downregulated)
and 34 were expressed more (upregulated) in the affected
individuals. Among those genes that were upregulated in
the affected individuals, 24 out of the 34 were expressed
with a log2 fold-change value greater than 1, and no genes
were found to be upregulated with a log2 fold-change value
greater than 2. Among those genes that were downregu-
lated in the affected individuals, 161 out of 179 were ex-
pressed with a log2 fold-change value less than 1, and
41 out of 179 were expressed with a log2 fold-change value
less than 2.The AmericanAmong the genes that were upregulated in the affected
boys, we found no obvious interpretable biological signal.
We present the results from the gene-set enrichment anal-
ysis performed on the set of genes that were downregu-
lated in the affected individuals with a log2 fold-change
value less than 1, because this set represents the genes
that were significantly downregulated and to a poten-
tially biologically relevant level. Transcription-factor-target
enrichment analysis revealed a significant enrichment of
genes regulated by E-box proteins (CANNTG promoter
motifs, Benjamini-Hochberg [BH]-corrected p value of
0.0052). KEGG-pathway enrichment analysis revealed an
enrichment of genes involved in Parkinson, Alzheimer,
and Huntington diseases and cardiac-muscle contraction
(BH-corrected p values of 2.95e7, 1.54e6, 2.13e6,
and 2.13e6, respectively). Enrichments in genes associ-
ated with HPO annotations included type 1 muscle-fiber
predominance, and laxity of ankles, fingers, and wrists
(all four phenotypes were reported with a BH-corrected
p value of 0.0481).
It is important to note that the RNA-seq results are
preliminary and potentially confounded by age- or sex-
specific expression differences between the affected and
unaffected groups, and the results here were derived from
a single family (because these were the samples that we
were able to collect to date). Complete blood counts were
not performed on the blood samples used for RNA-seq;
thus, our results could also be confounded by secondary
differences in mRNA abundances. The RNA-seq and
whole-genome sequencing data have been deposited to
the Sequence Read Archive (SRA) under BioProject ID
PRJNA301337.Journal of Human Genetics 97, 922–932, December 3, 2015 927
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Figure 3. Duplications Involving TAF1 from Families 10 and 11
(A) Pedigree drawings of families 10 and 11.
(B) The facial phenotype of proband 10A is notable for prominent supraorbital ridges, down-slanted palpebral fissures, sagging cheeks,
a long face, a high palate, and a pointed chin.
(C) Chromosome X cytobands are plotted above amore focused view of the region containing duplications that involve TAF1 in families
10 and 11. UCSC refGenes (from the UCSC Genome Browser tables) whose canonical transcript start or stop sites overlap either of the
two duplications are plotted.To evaluate structural CNS defects, we performed in vivo
functional modeling of TAF1 by using transient knock-
down in developing zebrafish embryos. The optic tectum
is a neuroanatomical structure that occupies the majority
of the space within the midbrain, and its size is a proxy
for head size (e.g., microcephaly,48 which is one of the
most robustly observed phenotypes).
We designed a splice-blocking morpholino (MO)
targeting the donor site of exon 9 of the sole zebra-
fish taf1 ortholog (Ensembl: ENSDART00000051196;
Figure S12) and performed stainings for acetylated
tubulin to evaluate the structure of the optic tectum. In
total, we analyzed 134 control embryos, 133 embryos in-
jected with taf1 MO, 109 embryos injected with taf1 MO
and wild-type (WT) TAF1 RNA, and 78 embryos injected
with WT TAF1 mRNA by measuring the area of the
optic tectum 3 days after fertilization. We found that
the relative area of the optic tectum was reduced by
approximately 10% in embryos injected with a MO
targeting the donor site of exon 9 of D. rerio taf1 (p <
0.0001; Figures 4A and 4B and S12). The effect was spe-
cific to the MO knockdown, given that the phenotype
could be reliably restored by co-injection of MO and
WT human TAF1 mRNA (p < 0.0001). Notably, overex-
pression of WT human TAF1 mRNA did not result in a928 The American Journal of Human Genetics 97, 922–932, Decembphenotype that was significantly different from that of
the controls (p ¼ 0.79).
To confirm these findings, we also used CRISPR/Cas9 to
disrupt taf1. For the CRISPR experiments, taf1 guide RNA
was generated as described.49 In agreement with our obser-
vation that the area of the optic tectum was smaller in
embryos injectedwith taf1MOthan in control embryos, F0
embryos with CRISPR-disrupted taf1 showed a smaller area
of this structure than did un-injected controls (p < 0.001)
(Figures 4C and S12). Unfortunately, the relatively small ef-
fects seen with MO knockdown and CRISPR-mediated
mosaicism in F0 embryos precluded us from being able
to show differences between WT and mutated TAF1 con-
structs in terms of rescuing the neuroanatomical defect
(data not shown).
In conclusion, we have presented evidence showing that
mutations involving TAF1 contribute to the phenotype
described here. Differences in genetic background and the
environment can certainly account for the phenotypic dif-
ferences among the various males in these families.50–56
Other studies also suggest a functional link between devel-
opmental delay and the TFIID multi-protein complex,10–12
although the phenotypic variability and expression of other
variants in TAF1 and in other TAFs remains to be deter-
mined. We have also provided the results of initial studieser 3, 2015
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Figure 4. Suppression or Genetic Mutation of Endogenous taf1 Induces Decreased Size of the Optic Tectum In Vivo
(A) Dorsal view of a control embryo (top) and an embryo injected with a morpholino (MO) targeting the donor site of exon 9 of D. rerio
taf1 3 days after fertilization. An antibody against a-acetylated tubulin was used for visualizing the axon tracts in the brain of evaluated
embryos. The assay consisted of measuring the area of the optic tectum (highlighted with the dashed ellipse), a neuroanatomical struc-
ture that occupies the majority of the space within the midbrain.
(B) A boxplot shows quantitative differences in the size of the optic tectum for each condition tested across three biological replicates.
Suppression of taf1 consistently induced a decrease of ~10% in the relative area of the optic tectum (p < 0.0001). The MO phenotype
could be restored by co-injection of MO and wild-type (WT) human TAF1mRNA (p< 0.0001), denoting the specificity of the phenotype
due to taf1 suppression. Overexpression of WT human TAF1 mRNA alone did not induce a phenotype that was significantly different
from that of controls (p¼ 0.79). The numbers of embryos evaluated per condition were as follows: control, 134; taf1MO, 133; taf1MOþ
WT TAF1 RNA, 109; and WT TAF1 RNA, 78.
(C) A boxplot shows quantitative differences in the size of the optic tectum between uninjected controls and F0 embryos with CRISPR-dis-
rupted taf1. The phenotype observed for bothMO-injected embryos and embryoswithCRISPR-disrupted taf1was concordant and reproduc-
ible across different experiments and across the two different methodologies. The p values were calculated with a Student’s t test.that suggests apossible regulatory role for at least onevariant
presented here and have shown that zebrafish knockdown
andmutant studies for this gene have demonstrated a quan-
tifiable, albeit small, effect on a neuronal phenotype. In our
current study, we did not see a clear mechanistic link be-
tween the missense and splice-site variants in some of the
probands and the duplications in two of the probands, and
the probands with duplications share fewer phenotypic fea-
tures with the rest of the disease cohort. There are many
possible explanations for why a duplication of a genemight
mimic the effect of a disruptive missense or splice-site
variant, and our current study lacks the necessary experi-
mental evidence to point to anyparticular scenariowith cer-
tainty. Further work is needed for teasing apart the contribu-
tions of these duplications and their constituent genes to
this more complex phenotype. It should also be noted that
exome and/or whole-genome sequencing has not yet been
performed in family 10 or 11, so other mutations could be
contributing to the phenotypes of the probands.Accession Numbers
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